Health-tech startup Medopad announces US expansion after $28m Series A

Health-tech firm Medopad is expanding into the US.

The company has signed a deal for an office in New York City, at the new JLABS office run by American pharma giant Johnson & Johnson (J&J).

Medopad chief exec Dan Vahdat said the move represents “a fantastic opportunity” for the London-headquartered business.

It follows a $28m Series A funding round clinched in February.

New York is home to the largest concentration of academic institutions in the world and boasts the country’s biggest bioscience workforce employed across 120 companies.

CEO Dan said: “We are thrilled to open a base in the USA as part of Johnson & Johnson’s incubator platform JLABS.

“This is a fantastic opportunity for Medopad as our values and vision are aligned with J&J’s leadership to help create a world where people can live longer.”

He added: “We value this partnership are looking forward to moving into our new office.”

Speaking further, Dan said Medopad has already worked in partnership with US pharmaceuticals, healthcare providers and academic institutions, including Baltimore-based teaching hospital and biomedical research facility Johns Hopkins Hospital.

He continued: “We look forward to strengthening these bonds and driving more innovative change for better health outcomes for people.”

Earlier this year, Medopad announced securing over £100m worth of commercial projects and partnerships during a business visit to China.